You are here:

liraglutide (Saxenda)

Advice

in the absence of a submission from the holder of the marketing authorisation:

liraglutide (Saxenda®) is not recommended for use within NHS Scotland.

Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of
• ≥ 30kg/m² (obese), or
• ≥ 27kg/m² to < 30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: liraglutide (Saxenda)
SMC Drug ID: 1247/17
Manufacturer: Novo Nordisk Ltd
Indication: As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of • ≥ 30kg/m² (obese), or • ≥ 27kg/m² to < 30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 8 May 2017

Back